NCT06757504View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASD

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 13, 2025

Primary Completion Date

February 6, 2026

Study Completion Date

May 8, 2026

Conditions
Autism Spectrum Disorder (ASD)
Interventions
DRUG

TTYP01 Tablets (12mg or 18mg)

Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.

DRUG

Placebo (Simulant TTYP01 Tablets)

Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.

Trial Locations (5)

Unknown

RECRUITING

Peking University Sixth Hospital, Beijing

NOT_YET_RECRUITING

The Second Xiangya Hospital of Central South University, Changsha

NOT_YET_RECRUITING

West China Hospital of Sichuan University, Chengdu

NOT_YET_RECRUITING

Nanjing Brain Hospital, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing

NOT_YET_RECRUITING

Tianjin Mental Health Center, Tianjin

All Listed Sponsors
lead

Shanghai Auzone Biological Technology Co., Ltd.

INDUSTRY